REG - Surgical Innovations - Exercise of Options, PDMR Shareholding & TVR

Surgical InnovationsAnnouncement

29/05/2019 15:10

RNS Number : 5112A
Surgical Innovations Group PLC
29 May 2019
 


 
                                                                           Surgical Innovations Group plc           
("SI Group" or "the Company")
 
Exercise of Options, PDMR Shareholding & Total Voting Rights
 
 
Exercise of Options
Surgical Innovations (AIM: SUN), the designer and manufacturer of innovative technology for minimally invasive surgery, announces that, on 24 May 2019, it issued and allotted a total of 1,500,000 ordinary shares of 1 penny each in the capital of the Company following an exercise of options by an employee of the Company.
               
PDMR Shareholding
The Company announces that, also on 24 May 2019, it issued and allotted a total of 1,500,000 ordinary shares of 1 penny each in the capital of the Company following an exercise of options by Charmaine Day, Company Secretary and PDMR.  As part of this transaction, Mrs Day sold 1,000,000 shares at a price of 4 pence per share. 
 
Following this transaction, the beneficial holding of Charmaine Day in the Company is 805,343 shares, representing approximately 0.1% of the issued share capital.
 
Application will be made to the London Stock Exchange for admission of the 3,000,000 ordinary shares to trading on AIM ("Admission") and it is expected that Admission will take place and that trading will commence on AIM on 4 June 2019.  
 
Total Voting Rights
Following Admission, the Company will have 790,566,177 ordinary Shares in issue with each share carrying the right to one vote. The Company has no ordinary Shares held in treasury. The total number of voting rights in the Company following Admission will therefore be 790,566,177.
 
 
 
For further information please contact:
 



Surgical Innovations Group Plc


www.sigroupplc.com




Nigel Rogers, Non-Executive Chairman


Tel: 0113 230 7597




Melanie Ross, Chief Financial Officer


















N+1 Singer (Nominated Advisor and Broker)


Tel: 020 7496 3000




Richard Lindley








Rachel Hayes


















Walbrook PR (Financial PR & Investor Relations)


Tel: 020 7933 8780 or si@walbrookpr.com




Paul McManus


Mob: 07980 541 893



 




 
 
 



1


Details of the person discharging managerial responsibilities/person closely associated




a)


Name


Charmaine Day




2


Reason for the notification




a)


Position/status


Company Secretary, Surgical Innovations Group plc




b)


Initial notification/ Amendment


Initial Notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


Surgical Innovations Group plc




b)


LEI


2138004GHGUH3HUZE156




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument, type of instrument
 
Identification code


Ordinary shares of 1p
 
 
 
GB0004016704




b)


Nature of the transactions


Exercise of 1,500,000 share options ("Exercise")
Sale of 1,000,000 Ordinary Shares of 1p ("Sale")




c)


Price(s) and volume(s)


 
 
 
 
 


Price(s)


Volume(s)


 
 
 
 
 
 




In relation to the Exercise:
1.575p
 
In relation to the Sale:
4p


 
1,500,000
 
 
1,000,000




 
 
 
 
 
 




d)


Aggregated information
-     Aggregated volume
-     Price


Not applicable, the Exercise and the Sale were each completed as single transactions
 
 
completed as




e)


Date of the transactions


 24 May 2019
 




f)


Place of the transactions


In respect of the Exercise, outside a trading venue
In respect of the Sale, London Stock Exchange, AIM Market (XLON)
 



 
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCLLFISESIAFIA